Hyderabad: Cell and gene therapy solutions provider Miltenyi Biotec on Monday announced the roll-out of what is touted as India’s first dedicated cell and gene therapy centre of excellence (CoE) — Miltenyi Innovation and Technology Centre (MITC) — in Hyderabad.
Spread over 1,800 sq metres in Genome Valley, MITC will foster innovation by integrating expertise, best practices, and cutting-edge technologies to combat diseases, including cancer. The company said it will also serve as a collaborative hub, hosting seminars and workshops in immunology, stem cell biology, cancer, and other key areas.
Dr Kathrin Misera-Lang, Consul General (Interim) of the Federal Republic of Germany, said the MITC launch in Hyderabad exemplifies the growing collaboration between India and Germany in biotechnology and healthcare. “This state-of-the-art facility will make significant contributions to the field of cell and gene therapies, improving healthcare outcomes and strengthening India’s leadership in life sciences,” she said.
Miltenyi Biomedicine managing director and Miltenyi Biotec BV & Co KG board member Dr Toon Overstijns said, “MITC is a pivotal step in accelerating the global revolution in cell and gene therapies. This centre reflects our ongoing commitment to advancing medical research and offering robust solutions in cell and gene therapy.”
Miltenyi Biotec BV & Co KG chief commercial officer and member of the board, Dr Boris Stoffel, said, “MITC will drive advancements in biomedical research, supporting the scientific and medical community in developing new therapies for diseases with limited treatment options. It will enable close collaboration with researchers, physicians, and industry, providing them with the tools and expertise needed to deliver transformative therapies to patients.”